Objectives. To adapt the self-administered comorbidity questionnaire (SCQ) into the Early Inflammatory Arthritis-SCQ (EIA-SCQ) and assess its clinimetric properties in EIA. Methods. The EIA-SCQ and indices of disease activity, function, pain, health-related quality of life (HRQoL) and health resource utilization were administered to 320 patients with EIA. Twenty patients completed the EIA-SCQ a second time 1 week later. Construct validity was evaluated by testing the hypotheses that a valid comorbidity index would correlate well with age, weakly with HRQoL and recent resource utilization and poorly with indices of disease activity, function and pain. Conclusions. The EIA-SCQ is reliable and valid for use in EIA. It has the potential to become a useful measure of comorbidity in outcome studies of EIA when the resources for a full medical chart review are unavailable.
Introduction
Comorbidity is the co-occurrence of different diseases in the same individual [1] and is an independent predictor of poorer health outcomes, including mortality, complication rates, length of stay, discharge to rehabilitation facilities or nursing homes, allocation of treatments, health services utilization and costs [2] [3] [4] [5] [6] [7] [8] [9] [10] . Of particular relevance to the study of inflammatory arthritis are the independent effects of comorbidity on outcomes such as function [4, [11] [12] [13] [14] , depression [13] , social support [8] and costs [15] . Indeed, among patients with arthritis, disability has been shown to rise exponentially with each additional chronic condition [2, 16] .
Commonly used comorbidity indices include the Charlson Comorbidity Index (CCI) [17] and the Index of Co-existent Disease (ICED) [18] . However, they require trained medical personnel to extract data from medical charts, are time-consuming to administer, and are limited by the availability and quality of the patient's medical records [19, 20] . An alternative is a self-report comorbidity questionnaire. Studies have shown that patients can accurately assess their current and past medical conditions, including comorbidities [21] [22] [23] [24] [25] . However, few self-report comorbidity instruments have been assessed for reliability and validity and, when done, not in patients with arthritis [22, [26] [27] [28] . One instrument, the self-administered comorbidity questionnaire (SCQ) [26] was developed and validated in patients admitted to general medical and surgical wards. We undertook to adapt this questionnaire as the Early Inflammatory Arthritis-SCQ (EIA-SCQ) and to assess its clinimetric properties in an outpatient population with EIA. 
Patients and methods

Patients
Study instrument
The original SCQ [26] lists 13 common medical conditions, including OA and RA as well as provides space to specify three optional health conditions in lay terms. The patient indicates if each condition is present, being treated and/or imposes functional limitation. 'Yes' responses are scored 1 point for a maximum score of 45. We adapted this instrument by removing the item 'RA' from the list of possible comorbidities and added instructions that we wished to identify problems aside from the patient's EIA (Appendix 1).
Measures of disease
Disease activity was assessed using the standard ACR joint count [29, 30] ), CRP and the Disease Activity Score 28 (DAS28) using the CRP [31] . Function was assessed with the HAQ -Disability Index (HAQ-DI) [32, 33] and pain with the Short-form McGill Pain Questionnaire (MPQ) [34, 35] .
Other measures
Health-related quality of life (HRQoL) was assessed with the Medical Outcomes Study Short Form 36 (SF-36) [36] and the World Health Organization Disease Assessment Schedule II (WHODAS II) [37] . Health services utilization was proxied by the number of doctor visits, number of tests and number of hours spent visiting physicians in the past 4 months [38, 39] .
Sample size justifications
The minimum sample size to measure test-retest reliability was determined by assuming an ICC of 0.85. A sample of 20 patients was required to obtain a 90% CI with a total width of 0.25 (0.125 on either side) [40, 41] .
Reliability
The first 20 consecutive patients seen as part of the McEAR that agreed to participate in the test-retest phase made up the subsample. These 20 patients were sent a second copy of the EIA-SCQ by mail exactly 1 week after they filled out their initial EIA-SCQ in order to reduce the possibility that rapid changes in health status could influence reporting.
Validity
Construct validity may be assessed by testing hypotheses of what a valid instrument would and would not correlate with [42] . We hypothesized that the EIA-SCQ would correlate with age and at least weakly with HRQoL. We hypothesized that the EIA-SCQ would not correlate with measures of disease activity, function, pain and health services utilization. Although health service utilization should in the long term correlate with comorbidity, this should not be the case in our newly diagnosed patients whose recent health care usage would likely reflect their new index disease.
Analysis
All statistical analyses were performed with SPSS v. 15 and the R statistical package. Test-retest reliability of the EIA-SCQ total score was measured using a two-way random effects model and single measure intra-class correlation coefficient. The -statistic tested for agreement with regard to the presence or absence of the comorbid condition between the two time points, as well for absolute agreement for all states across each diagnosis, i.e. the diagnosis itself, and whether the patient indicated he/she was receiving treatment for the condition and whether the condition limited activities. Construct validity was assessed between the EIA-SCQ and all construct measures using the conservative nonparametric Kendall's tau B correlation coefficient, with significance set at P < 0.05 [43] . 
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Results
Patient characteristics
The characteristics of the patients included in the study are presented in Table 1 . Test-retest reliability was assessed in a subset of 20 subjects. The retest sample was $65% female with a mean (S.D.) age of 55.2 (16.2) yrs and did not differ significantly from the larger cohort with respect to the demographic, disease status or other variables listed in Table 1 .
Test-retest reliability
The single measure ICC for the EIA-SCQ total score between time 1 and time 2 was 0.93 (95% CI 0.83, 0.97). Agreement for the presence or absence of individual comorbid conditions was almost perfect ( 5 0.8) for all comorbid conditions where kappa could be calculated except heart disease, which showed substantial agreement ( ¼ 0.64) ( Table 2 ). When testing for perfect agreement across all three response categories, there was perfect agreement for high blood pressure, lung disease, diabetes, kidney disease, liver disease, anaemia, depression and OA, almost perfect agreement for back pain ( ¼ 0.90) and moderate to substantial agreement for heart disease ( ¼ 0.64) ( Table 3) .
Construct validity
As hypothesized, the EIA-SCQ correlated moderately well with age (Tau B 0. Table 4) . 
Discussion
Reliability and validity
We have demonstrated that the EIA-SCQ, an adapted version of the original SCQ [26] , has adequate reliability and validity in an outpatient population with EIA. As expected, the mean total EIA-SCQ score of 3.7 (out of a maximum of 45) in this study was lower than that of 5.6 reported in the original study of inpatients by Sangha et al. [26] . Nevertheless, our reliability results were largely comparable with -values ranging from 0.64 to 1.0 compared with -values of 0.40-0.9 reported in the original study [26] . In terms of construct validity, consistent with our a priori hypotheses, the EIA-SCQ correlated well with age, a proxy for comorbidity [44, 45] , weakly with some aspects of function, HRQoL, resource utilization and pain, and negligibly with measures of disease activity and other aspects of HRQoL and resource utilization. As we expected measures of HRQoL to be more reflective of the recently diagnosed index disease than of comorbid conditions, the fact that there is only a weak correlation with the SF-36 MCS and the WHODAS II provides support for the construct validity of the EIA-SCQ. The fact that the EIA-SCQ score was not found to correlate with measures of disease activity and correlated weakly with measures of resource use in the last 4 months, supports the hypothesis that the EIA-SCQ measures diseases other than the index disease.
Limitations
We did not specifically assess the face validity of the questionnaire, but this had been assessed previously by looking at the associations between the SCQ and the Charlson Index on an item by item level and generally good agreement was found [26] . The revised introduction to the questionnaire provided no problems to participants.
It should be noted that, comorbid diseases were not very prevalent and in fact 9 of the 12 pre-defined diseases occurred in <15% of the patients. The large -values of 1.0 and the wide CIs for heart disease and back pain are almost certainly the result of the low prevalence of many of the pre-defined diseases and/or an unbalanced distribution of the comorbidity treatment activityderived variable.
We must also acknowledge the possibility of classification error by the patient. There may be some type of systematic bias, e.g. patients systematically tend to report that they do or do not have diabetes when the truth is the opposite or patients may not be able to differentiate between the category of OA/degenerative arthritis and their inflammatory arthritis. Furthermore, the categories are not mutually exclusive, e.g. a patient with lung cancer may classify their disease under lung disease or cancer, or both. Nevertheless, the good test-retest agreement that we have shown suggests that it is likely that the EIA-SCQ would demonstrate adequate criterion validity as did the original SCQ.
As for any study cohort, it is possible that our population does not represent all early inflammatory arthritis patients as there may be a self-inclusion bias, in that those who had RA vs undifferentiated arthritis may be more or less likely to have volunteered for this study.
Lastly, we were not able to assess the criterion validity of the EIA-SCQ, as was done for the original SCQ, by comparing it with a chart-based review using an accepted comorbidity index because of limited resources. It is possible that inpatients would be more aware of their illnesses than was the outpatient population we studied.
Need to measure comorbidity in EIA
Unlike previous studies in inflammatory arthritis [4, 11-15], we were not able to find strong correlations between comorbidity 
Summary
We evaluated the clinimetric properties of the EIA-SCQ and found that as predicted, the instrument had a moderate correlation with age, some correlation with recent health resource utilization, aspects of HRQoL and function and no correlation with measures of the index disease, except for a weak correlation with pain. Together these data suggest that the patients are clearly differentiating between their inflammatory arthritis and their comorbid conditions and support the construct validity of the EIA-SCQ.
Early Inflammatory Arthritis -self administered comorbidity questionnaire Instructions We would like to ask you about medical problems that you may have that may not be related to the type of arthritis that you have come to see your rheumatologist about.
The following is a list of common problems. Please indicate if you currently have the problem in the first column. If you do not have the problem, skip to next problem.
If you do have the problem, please indicate in the second column if you receive medications or some other type of treatment for the problem.
In the third column indicate if the problem limits any of your activities.
Finally, indicate all medical conditions that are not listed under ''other medical problems'' at the end of the page. 
